Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.

ABSTRACT:

Background

Cardiometabolic disease is a major cause of morbidity and mortality in persons with chronic kidney disease (CKD). Fractalkine (CX3CL1) is a potential mediator of both atherosclerosis and metabolic disease. Studies of the relationship of CX3CL1 with risk of cardiovascular disease (CVD) events and metabolic traits are lacking, particularly in the high-risk setting of CKD.

Study design

Cross-sectional and longitudinal observational analysis.

Setting & participants

Adults with CKD from 7 US sites participating in the Chronic Renal Insufficiency Cohort (CRIC) Study.

Predictor

Quartiles of plasma CX3CL1 levels at baseline.

Outcomes

Baseline estimated glomerular filtration rate from a creatinine and cystatin C-based equation, prevalent and incident C

SUBMITTER: Shah R 

PROVIDER: S-EPMC4516570 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature